We’ve supported the discovery, development and launch of hundreds of antimicrobial agents.

IHMA provides a full suite of technical capabilities and domain expertise in all phases of antimicrobial drug development: drug discovery, clinical development, regulatory approval and commercialization.

Why IHMA?

IHMA is a premier provider of antimicrobial drug development studies. With laboratories in both the US and Europe, we partner with clients around the world in the biotechnology, pharmaceutical, and diagnostic industries. We are a leading, independent laboratory specializing in surveillance studies and clinical trials, key milestones along the continuum from drug development to commercialization. We utilize state of the art technology, leading to first-class testing and data as well as sound economic frameworks. Our services can be customized to best align with our clients’ unique testing needs. This ensures successful drug development, commercialization, and post-marketing pathways.

Key Statistics

1,500 + Health Care Institutions Across More Than 80 Countries

Our relationships with hundreds of clinical sites across the world greatly facilitates our ability to conduct antimicrobial resistance surveillance so critical to a drug’s clinical development and commercialization and also supports our central laboratory microbiology services needed to conduct clinical trials.

100s of Thousands of Clinically Relevant Bacterial Isolates

Our Bacterial Repository is an expanding collection of clinically relevant pheno- and genotypically characterized bacterial pathogens. The organisms are catalogued according to a variety of key parameters and can be used to rapidly assemble custom collections to profile the anti-bacterial activities of any products in your discovery pipeline.

Over 1,000 Scientific Presentations and Publications

Our team of experienced clinical microbiologists and scientists have authored hundreds of abstracts, posters, slide presentations, peer-reviewed journal publications, and web accessible data and analysis that are so critical to educating the medical world about any new product.

Our fully integrated approach matters.

We provide a fully integrated programmatic approach to support all phases of drug development. This full spectrum of capabilities greatly facilitates client management efforts, provides access to globally available and fully harmonized facilities, and ensures one scientific team is providing access to in depth scientific expertise and ongoing project support.

We’re proud of our story

2017 marks our 25th anniversary. After spending two decades in the pharmaceutical industry in a variety of roles, Jack Johnson founded IHMA in 1992 to help pharmaceutical companies meet the challenges of the dynamic drug development landscape. Today, IHMA is one of the world’s leading providers of antimicrobial drug development support including emerging technology and services. Our team offers complete collaboration and flexibility with all of our clients around the world ensuring ongoing development success.

Global and US Leadership

Jack L. Johnson, M(ASCP), M.S., MBA

President & Chief Executive Officer

Jack L. Johnson, M(ASCP), M.S., MBA

President & Chief Executive Officer

Jack founded IHMA in 1992 after spending approximately 18 years in the pharmaceutical industry with Pfizer, Beecham Laboratories and G.D. Searle in various roles including, sales, marketing and management. During those years, he was responsible for the launch of cefoperazone, amoxicillin/clavulanic acid, ticarcillin/clavulanic acid, mupirocin and lomefloxacin. His responsibilities included both domestic and international assignments. Prior to joining the pharmaceutical industry, he spent a number of years in both hospital and private microbiology laboratories assuming various bench and management roles. Jack has degrees from Arizona State University and the University of Tennessee.

Daniel F. Sahm, PhD, D(ABMM), FAAM

VP Global Microbiology Services & Chief Scientific Officer

Daniel F. Sahm, PhD, D(ABMM), FAAM

VP Global Microbiology Services & Chief Scientific Officer

Dan has over 30 years of academic and industry experience focused on antimicrobial sciences and support of anti-infective research and product development. His experience spans the technical, clinical, regulatory, and business aspects required for all phases of product development. Dan has provided extensive expertise and has managed a wide array of laboratory services that have supported both small and large biopharmaceutical companies’ development of a wide variety of anti-infective products and strategies.

Dan received his Ph.D. in Microbiology and Immunology from Oklahoma University Health Sciences Center and was a Postdoctoral Resident in Medical and Public Health Laboratory Microbiology at the US Centers for Disease Control and Prevention. Subsequently he held faculty and microbiology laboratory director positions at the University of Chicago and Washington University Medical Centers. Most recently Dan was the Chief Scientific Officer for Eurofins Global Central Laboratory. Over his career Dan has presented and published over 500 scientific communications, and has provided editorial and other societal services for the American Society for Microbiology.

Karla Jordan-Elbrecht

Chief Financial Officer

Karla Jordan-Elbrecht

Chief Financial Officer

Karla Jordan-Elbrecht has been a transformative executive leader with experience guiding startups and legacy companies through extraordinary profit growth, market expansion and brand development. Karla, a DePaul University graduate, was the founder and CEO of a luxury brand located in Illinois, where she created and managed all aspects of both a brick-and-mortar and online store. She steered the company to success, developing strong brand recognition that led to expansive national presence in premier luxury and lifestyle magazines. Since 1997, Karla has been a leader at IHMA, Inc. where she has risen through the ranks to be the company’s CFO, this being accomplished through her ability to reconcile company vision with execution. Karla has proven an efficient financial and operational leader. She has consistently saved hundreds of thousands annually through exceptional contract negotiation, key relationship management and implementation of vital enterprise-wide training & development programs. For years, she has developed strategies and navigated the financial challenges and opportunities that a global enterprise experiences. Karla is a skilled leader who brings excellence and energy to the table and is prepared to tackle and successfully address a wide range of corporate challenges.

Brian M. Johnson

Vice President, Operations

Brian M. Johnson

Vice President, Operations

Brian has been with IHMA since 1994. He has been on the forefront of the design and implementation of many of the programs that IHMA offers and instrumental in IHMA’s growth and expansion. Currently, he is responsible for the day to day operations of the Clinical and Surveillance Project Management teams, Shipping and Logistics Department, Building Maintenance and Contracts Department. Brian has a Bachelor of Science degree from the University of Illinois.

Samuel K. Bouchillon, MD

Vice President & Medical Director

Samuel K. Bouchillon, MD

Vice President & Medical Director

Dr. Bouchillon received his undergraduate Bachelor of Science degree from the University of Tennessee, Knoxville and his Doctorate of Medicine from the University of Tennessee Medical Units, Memphis. Dr. Bouchillon has received his board certifications in the United States in both Pediatrics and Anesthesiology.

Dr. Bouchillon is currently the Medical Director in the department of Medical Microbiology and Vice President of International Health Management Associates, Inc., a diversified contract research organization located in the suburbs of Chicago, Illinois.

Dr. Bouchillon has published over 300 papers and abstracts in the area of infectious disease, antimicrobial resistance and antimicrobial surveillance. Current research interests include: molecular diagnostics, molecular basis of antimicrobial resistance, and the epidemiology of resistance in respiratory and hospital acquired pathogens.

Meredith M. Hackel, PhD, MPH

Laboratory Director

Meredith M. Hackel, PhD, MPH

Laboratory Director

Meredith was awarded her BS (Natural Resources), MPH (Hospital Epidemiology), and PhD (Molecular Epidemiology) from the University of Michigan before beginning her career at University Hospital in Ann Arbor.

Meredith has published and presented numerous papers and posters in the areas of infectious disease, molecular bacteriology and laboratory diagnostics. Current research interests include molecular diagnostics, and the epidemiology of antibiotic resistance in community and hospital acquired pathogens.

In 1985, Legionella hackeliae was named after Meredith who had isolated the organism during her work at University Hospital.

After working for over 15 years in the Clinical Microbiology Laboratory at University Hospital, as well as appointments in Washington state and Advocate Health Care Systems, she joined IHMA in 2002 as a Technical Specialist, moving to her present position as Laboratory Director and Laboratory Manager in 2006.

Krystyna M. Kazmierczak, PhD

Director, Molecular Services

Krystyna M. Kazmierczak, PhD

Director, Molecular Services

Krystyna is Director of the Molecular Laboratory at IHMA. She oversees projects that require molecular analyses, including characterization of antimicrobial resistance mechanisms as part of surveillance and new drug development studies. Her responsibilities include data review, data analysis and scientific writing.

Krystyna obtained her Ph.D. in Molecular Genetics and Cell Biology from the University of Chicago in 2001. She held research positions at Eli Lilly, Indiana University and the University of Illinois before joining IHMA as a Senior Molecular Scientist in June, 2013. She moved to her present position at IHMA in November, 2013.

Krystyna’s research interests have included the molecular biology and biochemistry of bacteriophage RNA polymerases, physiology and pathogenesis of Streptococcus pneumoniae, bacterial stress responses to treatment with antibiotics that disrupt protein or cell wall biosynthesis, and regulation of outer membrane proteins. Her current focus is on the mechanisms and epidemiology of antimicrobial resistance. She has authored or coauthored numerous manuscripts and posters presented at national and international conferences.

Robert E. Badal

Director, Business Development, North & South America

Robert E. Badal

Director, Business Development, North & South America

Bob joined IHMA in November 2005 as Director of New Business Development, bringing with him a wealth of experience in the diagnostics industry—especially the field of antimicrobial susceptibility testing. Prior to coming to IHMA, Bob worked at Dade Behring MicroScan for 23 years, serving in management roles in various areas including Research & Development, Technical Services, Customer Training, and Marketing. Two of his primary functions as Marketing Director, International, were to interface on behalf of MicroScan with the global pharmaceutical industry and to design the configurations of MicroScan’s antimicrobial susceptibility testing panels. Before joining Dade in 1982, Bob worked with Dr. Arthur Barry for 8 years as a research associate at the University of Calfornia, Davis, Medical Center in Sacramento, California, doing research on antimicrobial susceptibility testing and bacterial identification methodologies.

Randy A. Burk, MBA

Information Technology Director

Randy A. Burk, MBA

Information Technology Director

Randy has had over 25 years experience in the Information Systems field. He brings experience from Fortune 500 companies including General Motors, Baxter Healthcare, Brunswick Corporation and Wickes Lumber Company. He obtained a Master’s of Business Administration in Finance from the University of Wisconsin – Whitewater. His undergraduate work was in the Management of Computer Systems. He is a published author in networking trade journals. He specializes in data gathering, warehousing and analysis. He is the primary designer of the Surveillance Data Link Network, which combines the surveillance data from many disparate data sources into a single repository of reportable information.

Daryl J. Hoban, PhD, FCCM, D(ABMM), F(AAM)

Senior Consultant, Clinical Microbiology Sciences

Daryl J. Hoban, PhD, FCCM, D(ABMM), F(AAM)

Senior Consultant, Clinical Microbiology Sciences

Dr. Hoban received his undergraduate and graduate degree: Doctor of Philosophy (PhD) in Microbiology from the University of Manitoba and received his board certification in both Canada and the United States in Medical Microbiology and Public Health following a clinical microbiology fellowship. In 2006, he was elected as a fellow of the American Academy of Microbiology.
 
He is currently the Director of Clinical and Laboratory Services for International Health Management Associates Inc. in Schaumburg, IL, as well as a Professor in the department of Medical Microbiology, in the Faculty of Medicine, University of Manitoba and a Clinical Microbiologist at the Health Sciences Centre in Winnipeg, Canada.
 
Dr. Hoban has published over 600 papers and abstracts in the area of infectious disease, antimicrobial resistance and laboratory diagnostics. Current research interests include: molecular diagnostics, molecular basis of antimicrobial resistance, and the epidemiology of resistance in respiratory and hospital acquired pathogens.
 
In 2007 Dr. Hoban was awarded the ‘Distinguished Microbiologist Award’, at the 2007 CACMID/AMMI (Canadian Association of Clinical Microbiology and Infectious Diseases/Association of Medical Microbiology and Infectious Diseases) Conference in Vancouver.
 
Daryl has both a National and International reputation as a research leader in the area of Antibiotic resistant organisms (AROs). He has numerous publications, book chapters and invited presentations in this field.
 
Daryl is a recognized role model in clinical microbiology and is involved in the Clinical Microbiologist training program in Winnipeg through the University of Manitoba’s Department of Medical Microbiology. He is also the Chair of the Fellow of the Canadian College of Microbiology (FCCM) board exam process that provides certification for Clinical Microbiologists in Canada.

Europe Leadership

Stephen Hawser, PhD

CEO, IHMA Europe Sàrl

Stephen Hawser, PhD

CEO, IHMA Europe Sàrl

Stephen is CEO of IHMA Europe Sàrl, a wholly owned affiliate of International Health Management Associates, Inc. IHMA Europe Sàrl has state-of-the-art laboratories and is is based in Monthey, Switzerland and began operations in February 2009. Prior to joining IHMA, Stephen held several key positions in the pharmaceutical industry spanning around 15 years with focus in antibacterial and antifungal research and development. Hisindustry experience has come with his affiliations with Arpida (Switzerland), GlaxoWellcome (Italy), Hoechst Marion Roussel (France) and Marion Merrell Dow (Italy).
 
Prior to joining industry, Stephen earned his BSc (hons) in Microbiology (University of Aberdeen), PhD in biochemical toxicology (University of Dundee) and his post-doctorate on fungal catheter biofilms at the University of Glasgow. Stephen has regularly published at scientific conferences (>650 posters), in international peer-reviewed journals (>90 articles) and is co-inventor of a number of patents. In addition he is a reviewer for multiple journals and has actively participated at CLSI meetings since more than 15 years.

Sophie Magnet, PhD

Laboratory Director, IHMA Europe Sàrl

Sophie Magnet, PhD

Laboratory Director, IHMA Europe Sàrl

Sophie has been the Laboratory Director at IHMA Europe Sàrl since January 2014. She coordinates all laboratory-based activities performed at IHMA Europe in Monthey, Switzerland, from planning to data validation. She plays a central role in communication between business development and laboratory members.

Sophie carried-out her doctoral research at the Pasteur institute in Paris (France) and obtained her Ph.D. in microbiology from the University Paris VI (France) in 2001. She also got a degree of advanced study in management of technology from EPFL (Lausanne Federal School of Technology, Switzerland) in 2007.

Before joining IHMA Europe Sàrl, Sophie led research projects in the field of antimicrobial discovery, development and resistance in several academic laboratories (Biochemical Department of A. Einstein College of Medicine, NY (USA) from 2001 to 2004, Laboratories of Molecular Research on Antibiotics, INSERM, Paris (France) from 2004 to 2007, Laboratory of Bacterial Pathogenesis, EPFL (Switzerland) from 2007 to 2011, and Laboratory of Pharmacology of Anti-infective, INSERM, Poitiers (France) from 2012 to 2013). Her research has led to 23 original publications in peer-reviewed journals, 1 patent and several posters presented at international conferences.

Ian Morrissey, MBA, PhD, FRSM

Director of New Business & Project Development EMEA, IHMA Europe Sàrl

Ian Morrissey, MBA, PhD, FRSM

Director of New Business & Project Development EMEA, IHMA Europe Sàrl

Ian is Director of New Business and Project Development for Europe, Middle East and Asia at IHMA Europe Sàrl.

Since 1987, Ian has been actively engaged with the pharmaceutical industry to support the development of new antimicrobials, particularly pre-clinical and surveillance studies.

Ian obtained his Ph.D. from the School of Pharmacy, University of London (UK) in 1990 and Executive MBA from Imperial College Management School, University of London (UK) in 2001. Between 1990 and 1995, he held Research Fellowships at the School of Pharmacy, at Daiichi Pharmaceutical Co Ltd. (Japan) and at the University of East London (UK). After this Ian was a Lecturer and then Senior Lecturer at the University of Hertfordshire (UK) until 1998 when he joined GR Micro Ltd.

Ian was CEO at GR Micro Ltd. in London when the company was acquired by Quotient Bioresearch Ltd. in 2007 and continued as Director of Microbiology at Quotient until April 2012.

Ian is a Fellow of the Royal Society of Medicine and an enthusiastic supporter of the British Society for Antimicrobial Chemotherapy (BSAC). He is a former General Secretary of the BSAC and is currently Chairman of the BSAC Grants Committee. Ian is also a member of the BSAC Antimicrobial Susceptibility Testing Working Party and a member of BSAC Standing Committee on Antibacterial Drug Discovery and Development. He represents the BSAC on the Steering Committee for UK Standards for Microbiology Investigations. Ian is also an advisor to the Clinical Laboratory Standards Institute (CLSI) veterinary antimicrobial susceptibility standards subcommittee and is the sole or co-author of more than 200 publications/presentations on antimicrobial action and resistance.